Spruce Biosciences, Inc.
SPRB
$89.20
$6.097.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 697.00K | 1.30M | 2.91M | 4.91M | 7.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 697.00K | 1.30M | 2.91M | 4.91M | 7.10M |
| Cost of Revenue | 36.88M | 38.42M | 46.94M | 46.42M | 36.06M |
| Gross Profit | -36.18M | -37.12M | -44.03M | -41.51M | -28.96M |
| SG&A Expenses | 13.31M | 13.55M | 13.98M | 14.64M | 14.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.18M | 51.97M | 60.92M | 61.06M | 50.34M |
| Operating Income | -49.49M | -50.67M | -58.01M | -56.15M | -43.24M |
| Income Before Tax | -47.88M | -48.34M | -55.45M | -53.04M | -39.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.88 | -48.34 | -55.45 | -53.04 | -39.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.88M | -48.34M | -55.45M | -53.04M | -39.43M |
| EBIT | -49.49M | -50.67M | -58.01M | -56.15M | -43.24M |
| EBITDA | -49.46M | -50.63M | -57.97M | -56.11M | -43.19M |
| EPS Basic | -84.62 | -85.79 | -99.02 | -96.27 | -71.99 |
| Normalized Basic EPS | -52.89 | -53.62 | -61.89 | -60.17 | -44.99 |
| EPS Diluted | -84.62 | -85.79 | -99.02 | -96.27 | -71.99 |
| Normalized Diluted EPS | -52.89 | -53.62 | -61.89 | -60.17 | -44.99 |
| Average Basic Shares Outstanding | 2.29M | 2.28M | 2.24M | 2.20M | 2.19M |
| Average Diluted Shares Outstanding | 2.29M | 2.28M | 2.24M | 2.20M | 2.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |